Chapter 3: Use of ESAs and other agents**Excluding iron which is discussed in Chapter 2. to treat anemia in CKD-Reference-Cited by-同舟云学术

Chapter 3: Use of ESAs and other agents**Excluding iron which is discussed in Chapter 2. to treat anemia in CKD

Published:2012-08 Issue:4 Volume:2 Page:299-310
ISSN:2157-1716
Container-title:Kidney International Supplements
language:en
Short-container-title:Kidney International Supplements

Author:

Publisher

Elsevier BV

Subject

Nephrology

Reference87 articles.

1. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease;National Kidney Foundation;Am J Kidney Dis,2006

2. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target;National Kidney Foundation;Am J Kidney Dis,2007

3. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Section III. Clinical practice recommendations for anemia in chronic kidney disease in children;National Kidney Foundation;Am J Kidney Dis,2006

4. Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD;Bernhardt;J Am Soc Nephrol,2010

5. Transfusion medicine. First of two parts—blood transfusion;Goodnough;N Engl J Med,1999

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Differences in whole blood before and after hemodialysis session of subjects with chronic kidney disease measured by Raman spectroscopy;Lasers in Medical Science;2024-07-06

2. Association Between the Polymorphism of Angiotensin-Converting Enzyme Gene and Interleukin-1 Beta Gene and the Response to Erythropoietin Therapy in Dialysis Patients with Anemia;Balkan Journal of Medical Genetics;2023-12-01

3. The effect of oral zinc on hemoglobin and dose of erythropoietin in hemodialysis patients;Journal of Research in Medical Sciences;2023-12

4. The Resolution of a Cerebrovascular Accident With Phlebotomy in a Hemodialysis Patient With Sickle Cell Disease;Cureus;2023-11-16

5. Clinical questions and good practice statements of clinical practice guidelines for management of kidney injury during anticancer drug therapy 2022;Clinical and Experimental Nephrology;2023-10-25